ERBB2 and breast carcinoma: Third, the main arguments in favor of Trastuzumab were: i) better outcomes when Trastuzumab is administrated in combination with other forms of chemotherapy; ii) the dosage unit should be the same as in other countries; iii) the risk of cardiac toxicity should not be a limiting factor for the use of trastuzumab in patients with normal cardiac function; iv) HER2-positive breast cancer is more aggressive and it has higher death risk, which justifies the inclusion of trastuzumab.